Advancing Cellular Therapies: Alloplex’s SUPLEXA Platform Poised to Address Solid Tumor Challenges

In a recent interview with Immuno-Oncology Insights, Dr. Frank Borriello, CEO of Alloplex Biotherapeutics, discussed the potential of Alloplex’s SUPLEXA platform—a novel, autologous, non-engineered cellular therapy designed to treat solid tumors. Solid tumors have remained a significant challenge for many cell-based therapies, especially those relying on “off-the-shelf” approaches.